Keri Schaubert, Ph.D. Image

Keri Schaubert, Ph.D.


Cozen O'Connor

Keri, a Member at Cozen O’Connor, concentrates her practice on complex patent cases for clients in the pharmaceutical and biotechnology industries. She is a registered patent attorney and represents companies in Hatch-Waxman and biosimilar litigation. Keri handles all aspects of patent cases including pre-suit investigations, fact and expert discovery, dispositive motions, and trials. She also has experience in IPR matters at the PTAB on behalf of both patent owners and challengers.

Prior to attending law school, Keri received her Ph.D. in immunology from Wayne State University School of Medicine where, as a part of her doctoral research, she studied human CD8+ T cell responses to HIV epitopes and mimotopes thereof. Keri then completed a postdoctoral fellowship at the University of Michigan where she examined the role of transforming growth factor-? (TGF-?) in natural killer (NK) cell maturation. Keri has been published in numerous immunology journals.

Keri is a graduate of Loyola University Chicago School of Law, and earned a bachelor’s degree in biology and anthropology from the University of Michigan.

Recent Articles by Keri Schaubert, Ph.D.

The PTAB Puts Hatch-Waxman Defendants on Notice: File IPRs Early or Risk Fintiv Discretionary Denial

On September 16, 2020, the Patent Trial and Appeal Board (PTAB) denied institution of Mylan Labs Ltd.’s petition for IPR of U.S. Patent No. 9,439,906 (“the ’906 patent”) in IPR2020-00440.  In doing so, the PTAB exercised discretion to deny institution based on the six factors set forth in its precedential order in Apple Inc. v Fintiv Inc. For Hatch-Waxman Defendants interested in challenging the validity of Orange Book-listed patents at the PTAB, IPR petitions should be filed as early as possible in order to avoid this same result.